Our analysis has revealed that over the past 12 months, there has been a significant increase in the number, and variety of legal products on offer to Australian patients. Product prices have also fallen substantially as pricing competition has intensified.

Cost to patients remains highly variable, and are influenced not just by product type prescribed, but also by pharmacy margin, which fluctuates significantly, and by the dosage required to see benefits.

Despite this, prices paid by many patients fall within the limits of what is considered affordable. We expect product prices to continue to trend downwards, as more players enter the market and more streamlined, efficient supply chains are established.